Latest Conference Articles

Posters presented at the APhA 2024 Annual Meeting and Exposition discussed pharmacist barriers in pediatric immunizations, a novel meningococcal vaccine, and the need for inpatient reviews of vaccination history.

In a poster presented at the 2024 American Pharmacists Association Annual Meeting and Exposition, researchers addressed continuous glucose monitoring and its potential role in indigent communities.

According to Sa’ed Al-Olimat, education and advocacy are key to ensure a safe and accessible landscape of psychedelic therapeutics, especially as the compounds inch closer to the mainstream health care market.

In a poster presented at the 2024 American Pharmacists Association Annual Meeting and Exposition, researchers assessed state-level regulations for PBMs.

Researchers presented their findings on hypersensitivity caused by antibiotics as well as the best ways pharmacists can test for it.

In a conversation at this year’s American Pharmacists Association Annual Meeting & Exposition, Sa’ed Al-Olimat outlined the potential of psychedelic therapeutics in treating mental health disorders.

At this year’s American Pharmacists Association Annual Meeting & Exposition, Mark Garofoli urged pharmacists to develop strong documentation practices and go beyond baseline federal regulations to care for patients with red flags.

Pharmacists must uphold their “corresponding responsibility” to address controlled substance concerns among patients while balancing safety and respect, said Mark Garofoli at this year’s American Pharmacists Association Annual Meeting & Exposition.

The average US household spent $645 on OTC products in 2022.

The first nonprescription, OTC naloxone nasal spray (Narcan) was approved by the FDA in March 2023.

Medication therapy management can also increase the likelihood of using statins in this population.

Four posters presented at this year’s American Pharmacists Association Annual Meeting & Exposition assessed the potential impact of pharmacist interventions on improving mental health outcomes.

According to posters presented at the 2024 American Pharmacists Association Annual Meeting and Exposition, pharmacists wish to play a bigger role in educating young people about the risks of vaping.

Access to counseling and education were strong predictors of being dispensed contraceptives.

Results from a meta-analysis on the side of effects of the psychedelic psilocybin were presented at the 2024 American Pharmacists Association Annual Meeting & Exposition.

Four posters presented at the American Pharmacists Association Annual Meeting and Exposition explored how individuals and health care providers have been handling the COVID-19 pandemic.

A panel discussion at the Outcomes 2024 SYNC National Conference touched upon many important themes in community pharmacy, including the evolving role of pharmacists, emerging tech, and key challenges going forward.

Pacience Edwards, PharmD, manager of compliance at Outcomes, discussed during a session at Outcomes 2024 SYNC National Conference several specific opportunities at the pharmacists disposal.

Nicole Bernabe, CPhT, customer success specialist at TelePharm, discusses how the company is helping pharmacies increase operational efficiency while providing care to patients in need.

During a session at the Outcomes 2024 SYNC National Conference, Pacience Edwards, PharmD, manager of compliance at Outcomes, discussed the impacts that advancements in technology have had on pharmacy.

Pacience Edwards, PharmD, manager of compliance at Outcomes, discussed how technological solutions can aid pharmacies during a session at the Outcomes 2024 SYNC National Conference in Orlando, Florida.

Drug Topics sat down with Jude Dieterman, CEO of Outcomes, to discuss the value and uniqueness of the company in the pharmacy market, what’s next on the horizon, and the upcoming event.

Advocates can amplify the voices of transgender patients as they overcome barriers to health care, said Molly Crowther in a conversation at the 2023 Healthcare Advocate Summit.

Social determinants of health (SDOH), such as financial disparities or lack of insurance, create barriers to accessing breakthrough therapies like BTK inhibitors among patients with CLL and SLL.

Three posters presented at the 65th American Society of Hematology Annual Meeting and Exposition looked into the efficacy and safety of the therapies.

Data from the Surveillance, Epidemiology, and End Results (SEER) database were reviewed.

Six posters presented at the 65th American Society of Hematology Annual Meeting and Exposition looked at how treatments are impacting care for this patient population.

Understanding the adverse event profile of bispecific antibodies can aid treatment selection and improve patient outcomes.